Breathe Life Sciences (BLS), a subsidiary of Bioxyne, has entered into its first medicinal cannabis flower supply agreement in Costa Rica.
The deal involves Remidose LATAM, the Costa Rican arm of Canadian company Remidose Aerosols, a business specialising in precision-dosed metered THC inhalers and transdermal topical gels.
This latest arrangement builds on a December 2025 agreement between the two companies covering the supply of pastilles into Costa Rica and Panama.
Bioxyne said the deal, under which it will supply three Dr Watson-branded cannabis flower SKUs, constitutes the first international supply of medicinal cannabis flower into Costa Rica.
The first shipment is anticipated before June 30, with the opening invoice projected to exceed $500,000.
Chief executive Sam Watson said the broadened agreement demonstrated how rapidly opportunities can develop once a presence is established in growing markets.
"We've moved from our initial agreement into a broader supply scope in a short period of time, which reflects both the strength of the relationship and the level of demand we're seeing on the ground," he said.
"LATAM is still early in its development, but that's exactly where we see the opportunity.
“Being the first to supply branded medicinal cannabis flower into Costa Rica positions us ahead of competing suppliers and gives us the platform to expand into other LATAM jurisdictions as those markets continue to open.”
Remidose managing director Michael Mayne said: "We are pleased to be making the first ever shipment of medicinal cannabis flower into Costa Rica and are delighted to be doing this with the Dr Watson-branded products.
"Early indications of demand have been exceptionally strong – to the point where initial stock may well be fully committed before product even arrives in market. This is an exciting time for both companies."
